Source: VAERS.HHS.GOV
VAERS accepts reports of adverse events and reactions that occur following vaccination. Healthcare providers, vaccine manufacturers, and the public can submit reports to the system. While very important in monitoring vaccine safety, VAERS reports alone cannot be used to determine if a vaccine caused or contributed to an adverse event or illness. The reports may contain information that is incomplete, inaccurate, coincidental, or unverifiable. In large part, reports to VAERS are voluntary, which means they are subject to biases. This creates specific limitations on how the data can be used scientifically. Data from VAERS reports should always be interpreted with these limitations in mind.
The strengths of VAERS are that it is national in scope and can quickly provide an early warning of a safety problem with a vaccine. As part of CDC and FDA’s multi-system approach to post-licensure vaccine safety monitoring, VAERS is designed to rapidly detect unusual or unexpected patterns of adverse events, also known as “safety signals.” If a safety signal is found in VAERS, further studies can be done in safety systems such as the CDC’s Vaccine Safety Datalink (VSD) or the Clinical Immunization Safety Assessment (CISA) project. These systems do not have the same scientific limitations as VAERS, and can better assess health risks and possible connections between adverse events and a vaccine.
Key considerations and limitations of VAERS data:
VAERS data available to the public include only the initial report data to VAERS. Updated data which contains data from medical records and corrections reported during follow up are used by the government for analysis. However, for numerous reasons including data consistency, these amended data are not available to the public.
Chest pain; Difficulty breathing; Palpitations; Hyperventilation; This regulatory authority case was reported by an other health care professional and describes the occurrence of CHEST PAIN (Chest pain), DYSPNOEA (Difficulty breathing), PALPITATIONS (Palpitations) and HYPERVENTILATION (Hyperventilation) in a 13-year-old female patient who received mRNA-1273 (COVID-19 Vaccine Moderna) (batch no. 083F21B) for an unknown indication. No Medical History information was reported. On 30-Nov-2021, the patient received dose of mRNA-1273 (COVID-19 Vaccine Moderna) (Intramuscular) 1 dosage form. On 30-Nov-2021 at 2:00 PM, the patient experienced CHEST PAIN (Chest pain) (seriousness criterion hospitalization prolonged), DYSPNOEA (Difficulty breathing) (seriousness criterion hospitalization prolonged), PALPITATIONS (Palpitations) (seriousness criterion hospitalization prolonged) and HYPERVENTILATION (Hyperventilation) (seriousness criterion hospitalization prolonged). At the time of the report, CHEST PAIN (Chest pain), DYSPNOEA (Difficulty breathing), PALPITATIONS (Palpitations) and HYPERVENTILATION (Hyperventilation) was resolving. The action taken with mRNA-1273 (COVID-19 Vaccine Moderna) (Intramuscular) was unknown. For mRNA-1273 (COVID-19 Vaccine Moderna) (Intramuscular), the reporter did not provide any causality assessments. The patient was admitted in Hospital last 30-Nov-2021 due to paleness, cold extremities, chest pain, difficulty of breathing and hyperventilation. She was vaccinated with the first dose of the Moderna COVID-19 vaccine in the Left deltoid last 30-Nov-2021 in gymnasium during the 3-day National Vaccination activity. No concomitant medications were provided. No treatment medications were provided. Company Comment: This regulatory case concerns a 13-year-old, female patient with no medical history reported, who experienced the unexpected, serious events of chest pain, dyspnoea, palpitations and hyperventilation. The events, which resulted in hospitalization, occurred on the same day after administration of the first dose of the Moderna mRNA-1273 vaccine. Treatment information was not provided. However, the events were resolving at the time of the report. The rechallenge was not applicable as the events occurred after the first dose. The benefit-risk relationship of the Moderna mRNA-1273 vaccine is not affected by this report.; Sender's Comments: This regulatory case concerns a 13-year-old, female patient with no medical history reported, who experienced the unexpected, serious events of chest pain, dyspnoea, palpitations and hyperventilation. The events, which resulted in hospitalization, occurred on the same day after administration of the first dose of the Moderna mRNA-1273 vaccine. Treatment information was not provided. However, the events were resolving at the time of the report. The rechallenge was not applicable as the events occurred after the first dose. The benefit-risk relationship of the Moderna mRNA-1273 vaccine is not affected by this report.
Open in Wayback Machine
(If this is a foreign report without a description you will be able to read the description in the Wayback Machine on Medalerts if the report became public for the first time before November 18, 2022.)
Name | Dose # | Type | Manufacturer | Lot | Route | Site |
---|---|---|---|---|---|---|
COVID19 (COVID19 (MODERNA)) | 0 | COVID19 | MODERNA | 083F21B | OT | Unknown |
RECVDATE: | 01-07-2022 | RPT_DATE: |
CAGE_YR: | |
CAGE_MO: | |
DIED: | U |
DATEDIED: | |
L_THREAT: | U |
ER_VISIT: | |
HOSPITAL: | Y |
HOSPDAYS: | |
X_STAY: | U |
DISABLE: | U |
RECOVD: | N |
LAB_DATA: | |
V_ADMINBY: | |
OTHER_MEDS: | |
CUR_ILL: | |
HISTORY: | |
PRIOR_VAX: | |
SPLTTYPE: | PHMODERNATX, INC.MOD20214 |
FORM_VERS: | |
TODAYS_DATE: | 01-05-2022 |
BIRTH_DEFECT: | U |
OFC_VISIT: | U |
ER_ED_VISIT: | U |
ALLERGIES: | |
V_FUNDBY: |
Questions? Comments? Bugs?
[email protected]
Due to the high volume of inquiries, please be patient with response times.
AND PLEASE read the FAQ first.
OpenVAERS is a private organization that posts publicly available CDC/FDA data of injuries reported post-vaccination. Reports are not proof of causality.